Diabetes is conventionally managed with insulin or oral hypoglycemics, yet the global burden continues to rise, and side effects remain significant. Both Ray Peat and I have discussed the metabolic and anti-inflammatory roles of simple amino acids (like glycine) and natural quinones (like thymoquinone from Nigella sativa, black seed oil). Glycine supports collagen synthesis, anti-oxidation, and immune regulation, while thymoquinone has been shown to reduce oxidative stress and inflammation. However, their combination had not been formally investigated in a controlled diabetic model until now.
As the study below demonstrates, combining glycine with thymoquinone produces effects far superior to either compound alone — effectively normalizing fasting blood glucose, reversing insulin resistance (HOMA-IR), restoring beta-cell function (HOMA-%B), and completely protecting pancreatic histology in streptozotocin-induced diabetic rats. The synergistic antioxidant and anti-inflammatory effects were so pronounced that the combination group surpassed even healthy controls on several metrics, including body weight, GSH (glutathione), and insulin sensitivity.
The human-equivalent doses (HED) of the substances used in the study are 4.86 mg/kg for thymoquinone and 16.2 mg/kg for glycine. For a 70 kg adult, this translates to approximately 340 mg of thymoquinone and just 1.13 grams of glycine per day.
Once again, a simple amino acid (glycine) and a plant-derived quinone (thymoquinone) outperform standard monotherapies by addressing the root metabolic issues: oxidative stress, inflammation, and insulin resistance. The fact that the combination restored HOMA-%B (beta-cell function) to 101.9 — essentially normal — in a model of streptozotocin-induced beta-cell destruction is remarkable. This is what happens when you support cellular energy production and reduce reductive stress simultaneously. As always, these are animal data, but the magnitude of effect suggests human trials would be warranted. The quotes below support that conclusion, as does the previous work cited in the intro.
https://www.nature.com/articles/s41598-026-52735-w
“…Effects of thymoquinone and glycine treatments were appreciated, however effects of thymoquinone combined with glycine were much better. In conclusion, thymoquinone and glycine combination can effectively reduce both blood sugar and diabetic-associated complications through their synergistic, strong antioxidant and anti-inflammatory properties, which support the body’s natural cytoprotective ability.”
“…The most impressive outcome was seen with the combination, which brought levels down to nearly normal, around 73 mg/dL (vs. 410 in diabetics) and 4.07% HbA1C (vs. 9.38% in diabetics) (P < 0.05 vs. diabetes, Q, and G).”
“…Importantly, the combination (Q+G) yielded the most substantial improvements across all measured parameters. Insulin levels normalized to 2.85 µg/L, HOMA-IR decreased to 0.515, and both insulin sensitivity and β-cell function were markedly restored (HOMA-%S: 194.5; HOMA-%B: 101.9) with a QUICKI of 0.428 (P < 0.05 vs. diabetic, Q, and G).”
“…The Q+G combination produced the most intense enhancement, restoring GSH to 15.54 nmol/g tissue (vs. 2.15 in diabetics, P < 0.05 vs. all other groups)… MDA levels were significantly elevated in the diabetes group (7.72), with Q+G demonstrating the most significant decrease to 1.00 (P < 0.05 vs. diabetic, Q, and G).”
“…The combination of thymoquinone and glycine showed better efficient attenuation than the individual treatments… nearly normal acini, decreased inflammatory infiltration, and reduced hemorrhage.”
